PriceTargets.com logo

DRI Healthcare Trust - DHT.UN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$25.60
  • Forecasted Upside: 43.18%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
C$17.88 As of 10/16/2026 05:00 PM ET
▼ -0.17 (-0.94%)

This chart shows the closing price for DHT.UN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DRI Healthcare Trust Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DHT.UN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DHT.UN

Analyst Price Target is C$25.60
▲ +43.18% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DRI Healthcare Trust in the last 3 months. The average price target is C$25.60, with a high forecast of C$30.00 and a low forecast of C$23.00. The average price target represents a 43.18% upside from the last price of C$17.88.

This chart shows the closing price for DHT.UN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in DRI Healthcare Trust. This rating has held steady since June 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/16/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2026

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/22/2026National Bank FinancialBoost TargetOutperformC$23.50 ➝ C$25.50
8/11/2026Stifel NicolausBoost TargetBuyC$25.00 ➝ C$26.00
6/30/2026Canaccord Genuity GroupBoost TargetBuyC$22.25 ➝ C$23.00
6/30/2026Stifel NicolausBoost TargetBuyC$23.00 ➝ C$24.00
6/29/2026Raymond James FinancialBoost TargetStrong-BuyC$22.50 ➝ C$23.50
5/19/2026Stifel NicolausBoost TargetBuyC$22.00 ➝ C$23.00
5/19/2026National Bank FinancialBoost TargetOutperformC$22.50 ➝ C$23.50
5/19/2026ScotiabankBoost TargetSector OutperformC$25.00 ➝ C$30.00
4/2/2026Stifel NicolausBoost TargetBuyC$21.00 ➝ C$22.00
5/22/2025Royal Bank Of CanadaBoost TargetOutperformC$17.00 ➝ C$18.00
5/22/2025National Bank FinancialBoost TargetOutperformC$18.00 ➝ C$18.50
5/22/2025Canadian Imperial Bank of CommerceBoost TargetOutperformC$16.00 ➝ C$17.00
2/20/2025National Bank FinancialLower TargetOutperformC$19.50 ➝ C$17.50
12/12/2024Canadian Imperial Bank of CommerceLower TargetOutperformC$19.50 ➝ C$18.00
11/13/2024Raymond James FinancialLower TargetC$23.00 ➝ C$22.00
10/8/2024ScotiabankBoost TargetOutperformC$21.00 ➝ C$22.00
7/25/2024Truist FinancialLower TargetC$17.00 ➝ C$14.00
7/9/2024Stifel NicolausDowngradeBuy ➝ HoldC$22.00 ➝ C$15.00
7/9/2024Canadian Imperial Bank of CommerceLower TargetC$20.00 ➝ C$18.50
7/9/2024Royal Bank Of CanadaLower TargetC$20.00 ➝ C$16.00
7/9/2024National Bank FinancialLower TargetOutperformC$23.50 ➝ C$17.50
7/9/2024Raymond James FinancialDowngradeStrong-Buy ➝ OutperformC$24.00
5/8/2024Canaccord Genuity GroupLower TargetBuyC$19.50 ➝ C$19.00
5/8/2024Canadian Imperial Bank of CommerceBoost TargetOutperformC$19.50 ➝ C$20.00
3/1/2024National Bank FinancialBoost TargetOutperformC$22.00 ➝ C$23.50
3/1/2024Canadian Imperial Bank of CommerceBoost TargetOutperformC$19.00 ➝ C$19.50
3/1/2024Raymond James FinancialUpgradeOutperform ➝ Strong-BuyC$22.00 ➝ C$24.00
3/1/2024Stifel NicolausBoost TargetBuyC$21.00 ➝ C$22.00
2/2/2024National Bank FinancialBoost TargetOutperformC$18.50 ➝ C$22.00
2/2/2024Raymond James FinancialBoost TargetOutperformC$21.00 ➝ C$22.00
2/2/2024Canadian Imperial Bank of CommerceBoost TargetOutperformC$18.00 ➝ C$19.00
2/2/2024ScotiabankBoost TargetOutperformC$22.00 ➝ C$24.00
2/2/2024Stifel NicolausBoost TargetBuyC$20.00 ➝ C$21.00
11/28/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ OutperformC$18.00
(Data available from 10/16/2021 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2026

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

DRI Healthcare Trust logo
DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the TSX in Canadian dollars under the symbol 'DHT.UN' and in U.S. dollars under the symbol 'DHT.U'. To learn more, visit drihealthcare.com or follow us on LinkedIn.
Read More

Today's Range

Now: C$17.88
Low: C$17.88
High: C$18.24

50 Day Range

MA: C$17.84
Low: C$16.48
High: C$18.66

52 Week Range

Now: C$17.88
Low: C$14.28
High: C$19.75

Volume

18,651 shs

Average Volume

55,091 shs

Market Capitalization

C$982.74 million

P/E Ratio

N/A

Dividend Yield

3.33%

Beta

0.096953

Frequently Asked Questions

What sell-side analysts currently cover shares of DRI Healthcare Trust?

The following Wall Street sell-side analysts have issued reports on DRI Healthcare Trust in the last year: Canaccord Genuity Group Inc., National Bank Financial, Raymond James Financial, Inc., Scotiabank, and Stifel Nicolaus.
View the latest analyst ratings for DHT.UN.

What is the current price target for DRI Healthcare Trust?

0 Wall Street analysts have set twelve-month price targets for DRI Healthcare Trust in the last year. Their average twelve-month price target is C$25.60, suggesting a possible upside of 41.4%. Scotiabank has the highest price target set, predicting DHT.UN will reach C$30.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of C$23.00 for DRI Healthcare Trust in the next year.
View the latest price targets for DHT.UN.

What is the current consensus analyst rating for DRI Healthcare Trust?

DRI Healthcare Trust currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DHT.UN will outperform the market and that investors should add to their positions of DRI Healthcare Trust.
View the latest ratings for DHT.UN.

What other companies compete with DRI Healthcare Trust?

Other companies that are similar to DRI Healthcare Trust include Bausch Health Companies, Cronos Group, Cronos Group, Cara Operations and Knight Therapeutics. Learn More about companies similar to DRI Healthcare Trust.

How do I contact DRI Healthcare Trust's investor relations team?

DRI Healthcare Trust's physical mailing address is 100 King Street West, Suite 7250 PO Box 62, Toronto, ON M5X 1B1, Canada. The company's listed phone number is 416-863-1865. The official website for DRI Healthcare Trust is www.dricapital.com. Learn More about contacing DRI Healthcare Trust investor relations.